MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Biogen Inc

Closed

SectorHealthcare

131.24 -0.39

Overview

Share price change

24h

Current

Min

128.53

Max

133.55

Key metrics

By Trading Economics

Income

-122M

267M

Sales

-15M

2.5B

P/E

Sector Avg

12.24

63.778

EPS

3.44

Profit margin

10.865

Employees

7,605

EBITDA

-158M

536M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+45.75% upside

Dividends

By Dow Jones

Next Earnings

23 kwi 2025

Market Stats

By TradingEconomics

Market Cap

-982M

20B

Previous open

131.63

Previous close

131.24

News Sentiment

By Acuity

47%

53%

173 / 386 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

Biogen Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

6 wrz 2024, 11:00 UTC

Top News

Pandemic Darling Moderna Needs a Reality Check -- Heard on the Street -- WSJ

29 maj 2024, 15:56 UTC

Earnings
Acquisitions, Mergers, Takeovers

The Moderna Selloff Gains Steam. An Analyst Has a Few Theories Why. -- Barrons.com

Peer Comparison

Price change

Biogen Inc Forecast

Price Target

By TipRanks

45.75% upside

12 Months Forecast

Average 192.43 USD  45.75%

High 265 USD

Low 135 USD

Based on 25 Wall Street analysts offering 12 month price targets forBiogen Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

25 ratings

13

Buy

12

Hold

0

Sell

Technical Score

By Trading Central

N/A / 141.43Support & Resistance

Short Term

Strong Bearish Evidence

Intermediate Term

Bullish Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

173 / 386 Ranking in Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Biogen Inc

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.